Hear from two authors of an ACCC/LUNGevity Foundation study that identified key areas of clinician need related to biomarker testing in NSCLC.
While the identification of actionable biomarkers is fueling huge advancements in precision medicine and targeted therapies for the management of non-small cell lung cancer (NSCLC), access to these tests and associated therapies are not consistent throughout the healthcare system and have the potential to worsen existing health disparities.
Hear from two authors of an ACCC/LUNGevity Foundation study that identified key areas of clinician need related to biomarker testing in NSCLC, including increased guideline familiarity, practical applications of guideline-concordant testing, enhancing patient-clinician discussions and education, and access to appropriate clinical trials.
Guests:
Christopher S. Lathan, MD, MS, MPH
Chief Clinical Access and Equity Officer, Dana-Farber Cancer Institute;
Associate Medical Director, Dana-Farber at St. Elizabeth’s Medical Center;
Assistant Professor of Medicine, Harvard Medical School
Nikki Martin
Director of Precision Medicine Initiatives
LUNGevity Foundation
“Lung cancer has a lot of opportunities for treatment that impacts patients’ quality of life–even in the metastatic setting. If we don’t get the appropriate treatment to the appropriate patient, all these great [molecular] improvements that we’re making will continue to worsen disparities and equity.” - Christopher S. Lathan, MD, MS, MPH
This podcast is produced as part of the “Eliminating Precision Medicine Disparities” education program. Funding & support provided by Genentech, Janssen, Merck & Co., and Foundation Medicine.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
July 8, 2026
June 30, 2026
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
